Help Your Patients Get Cerefolin Brain Wellness™

Through Prescription or Online

Why Prescribing is Important

Prescribing Cerefolin Brain Wellness™ helps ensure patients with Mild Cognitive Impairment (MCI) stay on their care plan. You can provide expert guidance that helps your patients get the care they need, as well as targeted nutrition with clinically tested ingredients to help with brain health. A 90 day supply is sold only by prescription from Brand Direct Health® Pharmacy.

HCP Support Makes Prescribing Easy

Brand Direct Health® Pharmacy offers healthcare providers an efficient, easy-to-navigate process.

Seamlessly locate Cerefolin Brain Wellness™ in EMR systems, with detailed instructions.
Receive dedicated support from the Brand Direct Health® Pharmacy team for onboarding, refills, and prescribing assistance.
Get tailored education and resources for you and your patients from your Alfasigma Sales Consultant.

Patient Benefits from Prescribing Through Brand Direct Health®

89.5% of patients prescribed Cerefolin Brain Wellness™* refill their prescriptions through Brand Direct Health® Pharmacy.⁴

The value and benefits Brand Direct Health® provides help enable improved adherence as well as offer consistency and convenience, including:

A 90-day supply, available only by prescription, aligning with clinical findings on the importance of longer therapy for cognitive improvement.²
Automated refills to help maintain continuity and minimize lapses, shipped directly to the patient’s home.
Personalized support to answer any questions they may have, ensuring patients feel confident and informed.

A Convenient Online Option for Patients

If your patients prefer to buy Cerefolin Brain Wellness™ online without a prescription, they can buy 30- or 60-count packages through Cerefolin.com or Amazon. If they choose this option, please remind them the product is for use under medical supervision. This can help ensure regular follow-up to assess MCI symptoms.

Disclaimers

Cerefolin Brain Wellness™ is a targeted nutrition product for the clinical dietary management of mild cognitive impairment with hyperhomocysteinemia and is specially formulated to meet the distinctive nutritional requirements for this condition. Use under medical supervision.

§ Images don’t portray actual consumers and are for illustration purposes only.

|| Testimonials based on experience with CerefolinNAC®*.

* Cerefolin Brain Wellness™, formerly known and studied as CerefolinNAC®, is the same trusted and effective product that is now free from major allergens (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, sesame and soy), dyes, and colorants.

† By submitting this information, I hereby give Alfasigma USA, Inc. authorization to release, reproduce, use or distribute information about me, in original or modified form, for promotional and educational purposes in all forms of media, including print, broadcast or Internet. This information may include my medical information if I choose to submit any. I understand my information may be shared with a third party working on Alfasigma USA, Inc.’s behalf for promotional or educational purposes. I also understand that I may be contacted by this third party or Alfasigma USA, Inc. for more information.

^†† This product should be taken under medical supervision, and you should consult your healthcare provider before taking this for mild cognitive impairment.

References

Shankle WR, et al. J Alzheimer’s Dis. 2016 Oct 4;54(3):1073-1084
Shankle WR, et al. J Aging Res Clin Prac. 2013
Hara J, et al. Nutr Health Aging. 2015
Alfasigma USA. Data on File. PLUS Program: Patient Survey Results 2012. USA
Data on file. Support data 2019-2024. Alfasigma USA.
Chan A, et al. J Nutr Health Aging 2008;12(4):252-61.
de Jager CA. et al. Int J Geriatr Psychiatry. 2012 Jun:27(6):592-600.
Merrill E, et al. Am. J. Epidemiol. 2005 Oct;162(7):644-53.
Altern Med Rev 2000 Oct;5(5):467-71.
de Jager CA. Neurobiol Aging 2014;35(suppl 2):535-9.
Atkuri KR, et al. Curr Opin Pharmacol. 2007. 2007
N-acetylcysteine. Monograph. Alt Med Rev. 2000
Antoniades C, et al. Circulation. 2006.
Calderón-Ospina CA, et al. CNS Neurosci Ther. 2020.
Kimura, A.M et al. Alzheimer’s Dement. 2021.
Rogers JD, et al. Arch Neurol. 2003 Jan;60(1):59-64.
Smith AD, et al. J Alzheimer’s Dis.
Seshadri S, et al. N Engl J Med. 2002.
Yao Y, et al. J Geriatr Cardiol. 2017.
Diaz-Arrastia R, et al. Arch Neurol. 2000.
Keller, A.C., et al. J. Appl. Physiol. 2019.
Zhu Z, et al. Climacteric. 2020.
Estrada, D.A. et al. Am. J. Hematol. 2001.
Luzzi S, et al. Biomedicines. 2022.
Diekman, M. J. M., et al. Clin. Endocrinol. (Oxf) 2001.
Paknahad Z, et al. Int J Prev Med. 2012.
Desouza, C, et al. Drugs. 2002.
P. S. Myles et al. Br. J. Anaesth. 2008.
Fallah S, et al. J Clin Lab Anal. 2012.
Lerman, et al. AJMS., 2022.
Troen AM, et al. Proc Natl Acad Sci U S A. 2003.
Haj Mouhamed D, et al. Clin Chem Lab Med. 2011.